Growth Metrics

Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2019 - 2020)

Halozyme Therapeutics (HALO) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $52000.0 as the latest value for Q4 2020.